Article Information
- Received May 10, 2020
- Revision received September 14, 2020
- Accepted September 16, 2020
- Published online September 28, 2020.
Author Information
- Austin T. Akers,
- Skylar Y. Cooper,
- Zachary J. Baumgard,
- Gabriella P. Casinelli,
- Alicia J. Avelar and
- Brandon J. Henderson
- Department of Biomedical Sciences, Marshall University, Joan C Edwards School of Medicine, Huntington, WV 25703
- Correspondence should be addressed to Brandon J. Henderson at hendersonbr{at}marshall.edu.
Author contributions
Author contributions: B.J.H. designed research; A.T.A., S.Y.C., Z.J.B., G.P.C., A.J.A., and B.J.H. performed research; A.T.A., S.Y.C., Z.J.B., G.P.C., A.J.A., and B.J.H. analyzed data; B.J.H. wrote the paper.
Disclosures
The authors declare no competing financial interests.
This work was supported by the National Institutes on Drug Abuse at the National Institutes of Health Grant DA040047 (to B.J.H.). Research reported in this publication was supported by National Institute on Drug Abuse and Food and Drug Administration Center for Tobacco Products Grant DA046335 (to B.J.H.). Funding was also provided by the PhRMA Foundation (Predoctoral Fellowship in Pharmacology/Toxicology to S.Y.C.) and startup funds to B.J.H. by the Marshall University Research Corporation.
Funding
HHS | NIH | National Institute on Drug Abuse (NIDA)
DA040047; DA046335Pharmaceutical Research and Manufacturers of America Foundation (PhRMA Foundation)
Predoctoral Fellowship
Other Version
- You are viewing the most recent version of this article.
- previous version (September 28, 2020).
Article usage
In this issue
